Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Complement, coagulation and FcRn antibodies act on plasma protein cascades and on recycling of immunoglobulin G (IgG). Eculizumab, ravulizumab and pozelimab bind complement component C5 and block formation of the membrane attack complex. Sutimlimab inhibits C1s, the serine protease that initiates the classical complement pathway. Emicizumab bridges activated factor IX and factor X, while concizumab and marstacimab bind tissue factor pathway inhibitor (TFPI). Nipocalimab and rozanolixizumab block the neonatal Fc receptor (FcRn) and are used to study IgG half-life and clearance.
Synonyms: M281
Nipocalimab is a fully human, recombinant IgG1 monoclonal antibody engineered to lack Fc glycosylation. It binds with high affinity to the neonatal Fc receptor (FcRn), blocking the recycling and transcytosis of IgG. Nipocalimab is used in research on IgG-mediated autoimmune diseases, including hemolytic disease of the fetus and newborn (HDFN) and myasthenia gravis.
Tanruprubart is a monoclonal antibody engineered to target human complement C1q. This antibody binds specifically to C1q, effectively inhibiting the initiation of the classical complement activation pathway. By blocking this pathway, Tanruprubart demonstrates significant immunosuppressive properties, making it an invaluable tool for research into autoimmune and inflammation-related diseases. Its precise targeting offers potential for detailed studies on the role of complement activation in pathological conditions.
Synonyms: SYNT001; ALXN1830
Orilanolimab (SYNT001) is a humanized, de-immunized monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting the interaction between FcRn and the Fc portion of IgG molecules, Orilanolimab effectively impedes the activation of immune complexes (IC) mediated by FcRn. This action disrupts key pathways involved in IgG homeostasis, as well as innate and adaptive immune responses. This antibody is pivotal for research focused on the modulation of immune functions and the therapeutic regulation of antibody-mediated diseases.
Synonyms: NN 7415; mAb 2021; Anti-TFPI Recombinant Antibody
Concizumab, an IgG4 subtype monoclonal antibody, targets the Kunitz-type protease inhibitor 2 (KPI-2) structural domain of tissue factor pathway inhibitor (TFPI). By binding to this domain, Concizumab effectively inhibits the interaction between TFPI and the Factor Xa (FXa) active site. This antibody is particularly useful for research in hemophilia, providing insights into novel therapeutic interventions targeting coagulation pathways.
Synonyms: SKY59; RO7112689
Crovalimab (SKY59; RO7112689) is a novel humanized monoclonal antibody designed to target complement component 5 (C5) in a pH-dependent manner. It exhibits dissociation constants (K_D) of 15.2 nM at pH 7.4 and 16.8 μM at pH 5.8, reflecting its pH-responsive binding affinity. Additionally, Crovalimab demonstrates strong binding to human FcRn with a K_D of 17 μM at pH 6.0. This antibody effectively blocks the cleavage of C5 by C5 convertase and inhibits the activity of a specific C5 variant characterized by the p.Arg885His mutation. Furthermore, Crovalimab significantly inhibits the formation of the terminal complement complex C5b-9 across all three complement pathways: classical, lectin, and alternative. Due to these properties, Crovalimab is of significant interest for research into paroxysmal nocturnal hemoglobinuria (PNH) and other complement-mediated diseases, offering potential insights into novel therapeutic approaches.
Synonyms: C7E3
Abciximab (C7E3) is a chimeric monoclonal antibody fragment derived from both mouse and human sources, functioning as an inhibitor of glycoprotein (GP) IIb/IIIa. This agent effectively blocks platelet aggregation and leukocyte adhesion, mechanisms crucial for thrombosis and inflammatory responses, respectively. It achieves its therapeutic effects by targeting and binding to the GP IIb/IIIa receptor, as well as to vitronectin and Mac-1 receptors. This specificity makes Abciximab an essential tool in the study of platelet aggregation pathways and the development of anti-thrombotic therapies.
Synonyms: REGN3918
Pozelimab (REGN3918) is a fully humanized IgG4 monoclonal antibody specifically developed to target and bind with high affinity to complement component 5 (C5) and its variants. This antibody effectively inhibits the cleavage of C5, thereby blocking complement-mediated hemolysis. It is an essential tool for investigating the pathophysiology of complement-mediated disorders and is suitable for use in various research settings focused on these diseases.
